Navigation Links
Efficient Primary Structure Elucidation of Disulfide-bridged Peptides

e Procise cLC sequencing system

Highly accurate electrospray tandem mass spectrometry for the elucidation of disulfide-bridge patterns using the QSTAR Pulsar hybrid quadrupole time-of-flight mass spectrometer

Combination of two highly senisitive technologies provides information on complex disulfide structures

Methods

Sample Preparation: The multicomponent venom of the spider Cupiennius salei (Figure 1) was purified by a combination of gel filtration, cation exchange chromatography and reversephase HPLC1.

Edman sequencing: Two important neurotoxic peptides1,2,3, CSTX-1 (8'351.90 Da) and CSTX-9 (7'530.25 Da) were subjected to sequence determination by Edman degradation in a Procise cLC 492 protein sequencer. The reduced Efficient Primary Structure Elucidation of Disulfide-bridged Peptides Application Note Peptide Sequencing Tandem Mass Spectrometry www.appliedbiosystems.com Figure 1. Venom from Cupiennius salei was used in this study. and alkylated samples were sequenced up to Ile 53 (CSTX-1) and Ala 47 (CSTX-9), respectively. In order to secure the rest of the sequences, reduced and alkylated CSTX-1 was cleaved with endoproteinase Asp-N and chymotrypsin, CSTX-9 with endoproteinase Asp-N and immobilised trypsin. In each case the peptides generated were separated by RP-HPLC and identified by amino acid analysis and mass spectrometry. Native CSTX-1 and CSTX-9 were cleaved with immobilised trypsin to eliminate disulfide exchange during digestion, and iodoacetamide was added as a scavenger to alkylate any free thiol groups that may have been formed during cleavage. The tryptic peptides were separated by RP-HPLC and the disulfide-containing peptides were identified by amino acid analysis and by tandem mass spectrometry. Electrospray tandem mass spectrometry: Identification of the disulfide-bridge pattern was performed by nano-electrospra
'"/>

Source:


Page: All 1 2 3 4 5

Related biology technology :

1. Efficiently Insert Unique Restriction Sites into Plasmid Vectors
2. Efficient Cleavage of Fusion Proteins to Yield Native Amino Termini
3. Mammalian Expression Vector for Efficient Cloning of PCR Fragments
4. Efficient Transfection of Neurospora Crassa
5. Efficient Transfection of Neurospora Crassa
6. Efficient Recovery of Ultrapure Plasmid DNA
7. Efficient and Reliable PCR Setup Using Eppendorf MasterMix
8. Efficient DNA transfection of primary CNS neurons using TransMessenger Transfection Reagent
9. Efficient RNAi-mediated gene silencing in neuronal cells using QIAGEN siRNA and TransMessenger Transfection Reagent*
10. Cloning Based on Efficient Three-Fragment Assembly DNA Ligation
11. Efficient and Reliable Linear Amplification of cRNA

Post Your Comments:
(Date:11/23/2009)...ewswire/-InimexPharmaceuticals,Inc.announcedtodayt...tandCEO. ,, Abramsbringsmorethan25yearsofdrugdi...ventorofthenuclearmedicineimagingagent,Cardiolite,...wasManager,BiomedicalResearchWorldwide.In1996,Abra...esidentandCEOfrom1996to2006.AnorMEDdiscoveredandde...
(Date:11/20/2009)...untries have an opportunity to take the lead in tw...e University of Valencia (UV), working together wi...tive fabric of the Spanish biotechnology industry....ectors have more clout than those in English-speak...d and plants has been overlooked by the leading co...
(Date:11/20/2009)...20 Cell Therapeutics, In...at the Ninth Circuit Court of Appeals reversed a U... be allowed to pursue all of its claims against Th...t Court for trial. CTI filed a complaint against ...ment consultant for CTI,s product TRISENOX, in 200...
(Date:11/19/2009)...PRNewswire-FirstCall/ -- Omeros Corporation (Nasda...ults for the third quarter ended September 30, 200...Omeros reported a net loss of $3.9 million, or $1....llion, or $2.54 per share, for the same period in ..., the Company reported a net loss of $15.5 million...
Breaking Biology Technology:Inimex Announces Appointment of New CEO 2Spanish biotechnology should focus on food and plant sectors to be more competitive 2Cell Therapeutics Wins Federal Appeal to Pursue $22.8 Million Claim Against The Lash Group 2Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights 2Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights 3Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights 4Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights 5Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights 6Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights 7Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights 8
... ultra-high definition has potential to revolution..., there was a glimpse into the,future of women,s h...gery,that was recorded for the first time using "4...mally Invasive Gynecology hosted by the AAGL. AAGL...cialists in minimally,invasive gynecological techn...
...t. 30 Nutrition 21, Inc.,(Nasdaq: NXXI ) today a...,president and general manager of the Company,s Di...s. McWilliams has more than 22 years of,experience...lopment within,the direct response industry. Mrs. ...development, sales strategy, vendor operations and...
...Oct. 30 Insmed Inc. (Nasdaq:,INSM), a developer o...y,reported results for the third quarter and nine-...ighlights, -- Follow-on Biologics Program ...dicines and Healthcare products Regulator...tudy for the Company,s second follow-on biologic ...
Other Biology Technology:Women's Surgery Recorded for the First Time on '4K' Digital Cinema is Presented at the AAGL Congress 2Nutrition 21 Appoints Pam McWilliams, Vice President - General Manager of Direct Response 2Nutrition 21 Appoints Pam McWilliams, Vice President - General Manager of Direct Response 3Insmed Announces Financial Results for Third Quarter and Nine-Months Ended September 30, 2008 2Insmed Announces Financial Results for Third Quarter and Nine-Months Ended September 30, 2008 3Insmed Announces Financial Results for Third Quarter and Nine-Months Ended September 30, 2008 4Insmed Announces Financial Results for Third Quarter and Nine-Months Ended September 30, 2008 5Insmed Announces Financial Results for Third Quarter and Nine-Months Ended September 30, 2008 6Insmed Announces Financial Results for Third Quarter and Nine-Months Ended September 30, 2008 7Insmed Announces Financial Results for Third Quarter and Nine-Months Ended September 30, 2008 8Insmed Announces Financial Results for Third Quarter and Nine-Months Ended September 30, 2008 9Insmed Announces Financial Results for Third Quarter and Nine-Months Ended September 30, 2008 10
(Date:11/23/2009)...ng of recent discoveries about the multiple health...s multi-purpose nutrient, increased awareness of t... spurred research and even led to an appreciation ...ing from the health of your immune system to preve...nfluenza, vitamin D is now seen as one of the most...
(Date:11/23/2009)...of General Medical Sciences (NIGMS), part of the N...42.3 million for grants in scientific areas it ide...ed the GO grant program to stimulate biomedical re... American Recovery and Reinvestment Act (Recovery ...e to have a significant impact on a field of biome...
(Date:11/23/2009)...aled how environmental irritants such as air pollu... research published today in the American Journal...uthors of the study, from Imperial College London ...action inside the lungs that can trigger coughing ...n the air. They suggest that their findings may ul...
Breaking Biology News(10 mins):Multiple health concerns surface as winter, vitamin D deficiences arrive 2Multiple health concerns surface as winter, vitamin D deficiences arrive 3NIGMS invests in scientific Grand Opportunities with Recovery Act funds 2NIGMS invests in scientific Grand Opportunities with Recovery Act funds 3Research reveals exactly how coughing is triggered by environmental irritants 2Study Published in The Lancet Showed Significant Survival Benefit for Patients Facing Deadly Form of Lung Cancer 57732 1Study Published in The Lancet Showed Significant Survival Benefit for Patients Facing Deadly Form of Lung Cancer 57732 2Study Published in The Lancet Showed Significant Survival Benefit for Patients Facing Deadly Form of Lung Cancer 57732 3Study Published in The Lancet Showed Significant Survival Benefit for Patients Facing Deadly Form of Lung Cancer 57732 4Study Published in The Lancet Showed Significant Survival Benefit for Patients Facing Deadly Form of Lung Cancer 57732 5Study Published in The Lancet Showed Significant Survival Benefit for Patients Facing Deadly Form of Lung Cancer 57732 6Study Published in The Lancet Showed Significant Survival Benefit for Patients Facing Deadly Form of Lung Cancer 57732 7Study Published in The Lancet Showed Significant Survival Benefit for Patients Facing Deadly Form of Lung Cancer 57732 8Antigen Discovery Inc Awarded Grant for Chlamydia Vaccine Development 14163 1Antigen Discovery Inc Awarded Grant for Chlamydia Vaccine Development 14163 2Life Science Firms are Turning to Firmex to do Deals Online 14161 1Life Science Firms are Turning to Firmex to do Deals Online 14161 2Life Science Firms are Turning to Firmex to do Deals Online 14161 3
..., 2008 A discovery by Canada-U.S. biophysicists w...n to little ,nano-machines, or ,nano-valves, in ou...tic illnesses that attack muscles, the central ner...current issue of the Proceedings of the National ...e Universit de Montral and the University of Chica...
...stmas, and make way for a "green" holiday. Here ar...ronmentally friendly, courtesy of the American Che...c society, and the ACS Green Chemistry Institute. ...sign of chemical products and processes that elimi...To reduce your own personal carbon footprint and n...
... and hormone treatment for infertility give an inc... This comes from a new study from the Norwegian I...time mothers from the Norwegian Mother and Child C... Normal risk , First-time mothers who had not... 5.2 % risk of pre-eclampsia. , Risk after mis...
Other Biology News:Researchers advance knowledge of little 'nano-machines' in our body 2Miscarriage and infertility treatment increase pre-eclampsia risk 2
Normal Porcine Serum from Equitech-Bio
Anti-Foam Reagent from Promega
Viral CCI, Unconjugated, Fc Chimera from R&D Systems
GENOMIPHI V2 DNA AMP KIT 25RXN from GE Healthcare, formerly Amersham Biosciences
Biology Products: